CO2024009334A2 - Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2h-pirrolo[3',2':5,6]pirido[2,3-b][1,4]oxazepina - Google Patents
Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2h-pirrolo[3',2':5,6]pirido[2,3-b][1,4]oxazepinaInfo
- Publication number
- CO2024009334A2 CO2024009334A2 CONC2024/0009334A CO2024009334A CO2024009334A2 CO 2024009334 A2 CO2024009334 A2 CO 2024009334A2 CO 2024009334 A CO2024009334 A CO 2024009334A CO 2024009334 A2 CO2024009334 A2 CO 2024009334A2
- Authority
- CO
- Colombia
- Prior art keywords
- oxazepine
- pyrido
- bcl
- pyrrolo
- tetrahydro
- Prior art date
Links
- -1 1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Chemical compound 0.000 title 1
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263267018P | 2022-01-21 | 2022-01-21 | |
| PCT/US2023/060944 WO2023141536A1 (en) | 2022-01-21 | 2023-01-20 | 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024009334A2 true CO2024009334A2 (es) | 2024-07-18 |
Family
ID=85382827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0009334A CO2024009334A2 (es) | 2022-01-21 | 2024-07-15 | Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2h-pirrolo[3',2':5,6]pirido[2,3-b][1,4]oxazepina |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11964990B2 (https=) |
| EP (1) | EP4466273A1 (https=) |
| JP (2) | JP7714811B2 (https=) |
| KR (1) | KR20240136972A (https=) |
| CN (1) | CN119053610A (https=) |
| AR (1) | AR128310A1 (https=) |
| AU (1) | AU2023210279A1 (https=) |
| CA (1) | CA3242074A1 (https=) |
| CO (1) | CO2024009334A2 (https=) |
| IL (1) | IL312709A (https=) |
| MX (1) | MX2024008840A (https=) |
| TW (1) | TW202340210A (https=) |
| WO (1) | WO2023141536A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11964990B2 (en) * | 2022-01-21 | 2024-04-23 | Abbvie Inc. | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors |
| CN117820134A (zh) * | 2024-01-10 | 2024-04-05 | 山东盛安贝新材料有限公司南京分公司 | 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018322059C1 (en) | 2017-08-23 | 2024-09-12 | Guangzhou Lupeng Pharmaceutical Company Ltd. | BCL-2 inhibitors |
| US12220419B2 (en) | 2018-08-22 | 2025-02-11 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| KR20220158725A (ko) | 2020-02-24 | 2022-12-01 | 광조우 루펭 파마슈티칼 컴퍼니 엘티디. | Bcl2 억제제를 함유하는 핫 멜트 압출 고체 분산체 |
| US11964990B2 (en) * | 2022-01-21 | 2024-04-23 | Abbvie Inc. | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors |
-
2023
- 2023-01-19 US US18/156,987 patent/US11964990B2/en active Active
- 2023-01-19 TW TW112102814A patent/TW202340210A/zh unknown
- 2023-01-20 AU AU2023210279A patent/AU2023210279A1/en active Pending
- 2023-01-20 WO PCT/US2023/060944 patent/WO2023141536A1/en not_active Ceased
- 2023-01-20 CA CA3242074A patent/CA3242074A1/en active Pending
- 2023-01-20 AR ARP230100132A patent/AR128310A1/es unknown
- 2023-01-20 MX MX2024008840A patent/MX2024008840A/es unknown
- 2023-01-20 KR KR1020247023725A patent/KR20240136972A/ko active Pending
- 2023-01-20 JP JP2024540933A patent/JP7714811B2/ja active Active
- 2023-01-20 CN CN202380016422.5A patent/CN119053610A/zh active Pending
- 2023-01-20 IL IL312709A patent/IL312709A/en unknown
- 2023-01-20 EP EP23707582.5A patent/EP4466273A1/en active Pending
-
2024
- 2024-03-05 US US18/595,898 patent/US20250066388A1/en not_active Abandoned
- 2024-07-15 CO CONC2024/0009334A patent/CO2024009334A2/es unknown
-
2025
- 2025-07-02 US US19/258,642 patent/US20260028356A1/en active Pending
- 2025-07-15 JP JP2025118767A patent/JP2025160251A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240136972A (ko) | 2024-09-19 |
| WO2023141536A1 (en) | 2023-07-27 |
| US11964990B2 (en) | 2024-04-23 |
| JP7714811B2 (ja) | 2025-07-29 |
| IL312709A (en) | 2024-07-01 |
| CN119053610A (zh) | 2024-11-29 |
| JP2025160251A (ja) | 2025-10-22 |
| AR128310A1 (es) | 2024-04-17 |
| AU2023210279A1 (en) | 2024-05-23 |
| US20250066388A1 (en) | 2025-02-27 |
| US20260028356A1 (en) | 2026-01-29 |
| EP4466273A1 (en) | 2024-11-27 |
| JP2025504382A (ja) | 2025-02-12 |
| MX2024008840A (es) | 2024-07-25 |
| TW202340210A (zh) | 2023-10-16 |
| US20230234971A1 (en) | 2023-07-27 |
| CA3242074A1 (en) | 2023-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024009334A2 (es) | Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2h-pirrolo[3',2':5,6]pirido[2,3-b][1,4]oxazepina | |
| CU20210015A7 (es) | COMPUESTOS DE PIRAZOLO [3.4-b] PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
| CO2019004650A2 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| CO2022008091A2 (es) | Inhibidores de kras g12c | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| CR20190224A (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| CY1120179T1 (el) | Ετεροκυκλικη ενωση που περιεχει αζωτο ή αλας αυτης | |
| UY27234A1 (es) | Inhibidores novedosos de tirosina cinasa | |
| DOP2005000064A (es) | Nuevos compuestos | |
| DOP2002000422A (es) | Agentes antibacterianos. | |
| MX385838B (es) | Derivados de 3-tetrazolil-bencen-1,2-disulfonamida como inhibidores de metalo-beta-lactamasa. | |
| CR20140216A (es) | 5,7-imidazo[1,2-c]pirimidinas sustituidas | |
| CR20230485A (es) | Derivados de fósforo como nuevos inhibidores de sos1 | |
| UY26889A1 (es) | Compuestos farmacéuticos | |
| ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| SA519401614B1 (ar) | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب | |
| PA8561501A1 (es) | Lactamas como antagonistas de taquiquininas | |
| CO2024014618A2 (es) | Inhibidores de malt-1 de tiazolo[5,4-b]piridina | |
| PY2000386A (es) | Compuestos de quinolina como inhibidores de quinasas tam y met | |
| UY28535A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
| CO2023012702A2 (es) | Derivados de diazepina útiles en el tratamiento de clostridium difficile | |
| DOP2002000386A (es) | Agentes antibacterianos | |
| ECSP088968A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| UY39570A (es) | Inhibidores de la tirosina quinasa de bruton de pirazol bicíclico | |
| CO2025010725A2 (es) | Compuestos moduladores de receptores de dopamina d3/d2 |